Effect of release‐controlled nifedipine on portal hemodynamics in cirrhotic patients

Qin Chengyong, Li Dongxing, Zhu Juren, Fu Lina, Wang Zhaohai, Z. Guoquan, Jia Tao
{"title":"Effect of release‐controlled nifedipine on portal hemodynamics in cirrhotic patients","authors":"Qin Chengyong, Li Dongxing, Zhu Juren, Fu Lina, Wang Zhaohai, Z. Guoquan, Jia Tao","doi":"10.1046/J.1443-9573.2001.00016.X","DOIUrl":null,"url":null,"abstract":"OBJECTIVE: To evaluate the therapeutic effect of release-controlled nifedipine on portal hypertension. \n \n \n \nMETHODS: Thirty-two cirrhotic patients were enrolled to investigate, by using duplex Doppler ultrasonography, differences in portal hemodynamics before and after treatment with release-controlled nifedipine (30 mg once per day). \n \n \n \nRESULTS: After taking nifedipine, the diameter, blood velocity and blood flow of the portal vein decreased, but only the change in velocity was statistically significant. After treatment, the congestion index increased, and the blood velocity and blood flow of the splenic vein significantly decreased. The resistance and pulsatile indices of the right hepatic and splenic arteries also decreased markedly. The total hepatic blood flow was elevated slightly and there were no significant changes in mean arterial pressure and heart rate. \n \n \n \nCONCLUSIONS: The resistance and pulsatile indices of the hepatic and splenic arteries are representative indices of portal resistance. Release-controlled nifedipine may decrease portal pressure by the following mechanisms: (i) decrease of systemic blood pressure triggers the sympathetic reflex, leading to splanchnic artery constriction and portal blood flow reduction; (ii) dilatation of the portal vein and sinusoids leads to decrease portal resistance; and (iii) dilatation of the collateral veins. Nifedipine has no significant effect on systemic circulation in normotensive cirrhotic patients, therefore it has good prospects as a drug for clinical use in portal hypertension.","PeriodicalId":10082,"journal":{"name":"Chinese journal of digestive diseases","volume":"11 1","pages":"34-37"},"PeriodicalIF":0.0000,"publicationDate":"2001-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese journal of digestive diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1046/J.1443-9573.2001.00016.X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

OBJECTIVE: To evaluate the therapeutic effect of release-controlled nifedipine on portal hypertension. METHODS: Thirty-two cirrhotic patients were enrolled to investigate, by using duplex Doppler ultrasonography, differences in portal hemodynamics before and after treatment with release-controlled nifedipine (30 mg once per day). RESULTS: After taking nifedipine, the diameter, blood velocity and blood flow of the portal vein decreased, but only the change in velocity was statistically significant. After treatment, the congestion index increased, and the blood velocity and blood flow of the splenic vein significantly decreased. The resistance and pulsatile indices of the right hepatic and splenic arteries also decreased markedly. The total hepatic blood flow was elevated slightly and there were no significant changes in mean arterial pressure and heart rate. CONCLUSIONS: The resistance and pulsatile indices of the hepatic and splenic arteries are representative indices of portal resistance. Release-controlled nifedipine may decrease portal pressure by the following mechanisms: (i) decrease of systemic blood pressure triggers the sympathetic reflex, leading to splanchnic artery constriction and portal blood flow reduction; (ii) dilatation of the portal vein and sinusoids leads to decrease portal resistance; and (iii) dilatation of the collateral veins. Nifedipine has no significant effect on systemic circulation in normotensive cirrhotic patients, therefore it has good prospects as a drug for clinical use in portal hypertension.
控释硝苯地平对肝硬化患者门静脉血流动力学的影响
目的:评价控释硝苯地平治疗门静脉高压症的疗效。方法:采用双多普勒超声检查32例肝硬化患者,观察缓释硝苯地平(30 mg / d)治疗前后门静脉血流动力学的差异。结果:服用硝苯地平后,门静脉直径、血流速度和血流量均下降,但仅血流速度变化有统计学意义。治疗后充血指数升高,脾静脉血流速度和血流量明显减少。右肝动脉和脾动脉的阻力指数和搏动指数也明显下降。肝总血流量略有升高,平均动脉压和心率无明显变化。结论:肝动脉和脾动脉的阻力和搏动指标是门静脉阻力的代表性指标。释放控制硝苯地平可能通过以下机制降低门静脉压力:(1)全身血压降低触发交感反射,导致内脏动脉收缩,门静脉血流减少;(ii)门静脉和窦状窦扩张导致门静脉阻力降低;(三)侧静脉扩张。硝苯地平对正常血压肝硬化患者的体循环无明显影响,作为门静脉高压症的临床治疗药物具有良好的应用前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信